Every 8-K that PROVECTUS BIOPHARMS (PVCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVCT filings page.
Provectus Biopharmaceuticals, Inc. is converting accrued but unpaid directors’ fees into equity. The Board approved turning $542,500.00 of fees owed through June 30, 2026 into shares of the company’s Series D-1 Preferred Stock at $2.862 per share.
This will result in 189,554 shares of Series D-1 Preferred Stock, which are convertible into 1,895,540 shares of common stock. The preferred shares are being issued to satisfy outstanding cash fees and are not a separate award under the 2024 Equity Compensation Plan.
Provectus Biopharmaceuticals, Inc. held its annual stockholder meeting on June 18, 2026, where five proposals were decided. Stockholders elected four directors to one‑year terms, with each nominee receiving over 191 million votes in favor, plus 131,619,889 broker non‑votes reported on this item.
They approved an advisory vote on executive compensation, with 190,162,705 votes for and 16,667,960 against, and ratified CBIZ CPAs P.C. as independent registered public accounting firm for 2026 with 329,742,597 votes for. Stockholders also authorized the board to implement a reverse stock split of common and certain preferred stock at a ratio between 1‑for‑10 and 1‑for‑50, and to proportionally reduce authorized common and preferred shares using the same ratio once selected by the board.
Provectus Biopharmaceuticals, Inc. filed a current report describing information to be shared at its June 18, 2026 annual meeting of stockholders. The company plans to update stockholders on clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.
The accompanying 2026 Annual Meeting of Stockholders presentation slides are attached as Exhibit 99.1. This material is furnished under Regulation FD and is not deemed filed under the Securities Exchange Act of 1934.
Provectus Biopharmaceuticals, Inc. is scheduling its 2026 Annual Meeting of Stockholders for June 18, 2026 at 4:00 p.m. Eastern Time at Perkins Place in Knoxville, Tennessee, which is planned to become the company’s new headquarters.
The company intends to relocate from its current offices at 800 S. Gay Street, Suite 1610, to Perkins Place in 2026. April 20, 2026 is the record date, and stockholders will receive a notice of internet availability with instructions to access the definitive proxy materials.
Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on rose bengal sodium, with programs in oncology, dermatology, ophthalmology, and several additional proof-of-concept areas.
Provectus Biopharmaceuticals, Inc. amended the terms of its Series D and Series D-1 Convertible Preferred Stock to push back when these preferred shares automatically convert into common stock. The automatic conversion date, previously set at June 20, 2026, is now December 31, 2028.
The amendments were approved by the board of directors and a special committee made up entirely of independent directors, and were filed with the Delaware Secretary of State. The changes affect only the timing of automatic conversion, not the existence of the preferred stock itself.